Abstract: An orally administered pharmaceutical agent that is particularly suited for iron and magnesium substitutive therapy is disclosed. This drug consists of a combination of one or more pharmaceutically and physiologically compatible iron compounds, one or more pharmaceutically and physiologically compatible magnesium compounds, and, if the magnesium compounds do not contain any chlorine atoms dissociable in aqueous media and saturating the available magnesium valences, the drug further consists of one or more pharmaceutically and physiologically compatible compounds providing chlorine ions in aqueous media. The iron compounds, magnesium compounds and chlorine ion supplying compounds may be mixed with the conventional pharmaceutical solvents and/or thinners and/or auxiliary matter. Unexpectedly, this drug makes it possible to simultaneously administer magnesium or calcium compounds with iron compounds, without thereby causing reduced iron resorption.

Abstract: The invention relates to an agent for the prophylaxis of cardiac infarcti and for the prevention or reinfarctions, and is characterized by the fact that said agent comprises a combination of magnesium amino dicarboxylic acid halides, basic magnesium amino dicarboxylic acid salts, and magnesium halides, singly or in combination, on the one hand, and acetylsalicylic acid, on the other hand, as well as conventional pharmaceutical carriers, diluents, and/or adjuvants, as required.